The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group.
about
Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the lMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingMultiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsIdentification of proteins found to be significantly altered when comparing the serum proteome from Multiple Myeloma patients with varying degrees of bone disease.unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?Sotatercept in patients with osteolytic lesions of multiple myeloma.Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management.Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1α levels in patients with MGUS.Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo stagingInternational Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease.The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects.Osteoporosis and osteopenia: implications for periodontal and implant therapy.Prevention and treatment of myeloma bone disease.Management of bone disease in multiple myeloma.Current Controversies in the Management of Myeloma Bone Disease.Extracellular matrix and the myeloid-in-myeloma compartment: balancing tolerogenic and immunogenic inflammation in the myeloma niche.MGUS to myeloma: a mysterious gammopathy of underexplored significance.An Evidence-Based Approach to Myeloma Bone Disease.The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.Myeloma impairs mature osteoblast function but causes early expansion of osteo-progenitors: temporal changes in bone physiology and gene expression in the KMS12BM model.Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma.Measurement of β-isomerized C-terminal telopeptide of type I collagen in patients with POEMS syndrome: diagnostic, prognostic, and follow-up utilitiesExpression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates.Study of bone metabolism and angiogenesis in patients undergoing high-dose chemotherapy/autologous hematopoietic stem cell transplantation.Bisphosphonate guidelines for treatment and prevention of myeloma bone disease.Prospective study of signalling pathways in myeloma bone disease with regard to activity of the disease, extent of skeletal involvement and correlation to bone turnover markers.Reliability and validity of the Greek QLQ-C30 and QLQ-MY20 for measuring quality of life in patients with multiple myeloma.Clinical significance of osteoblast precursors and osteoclast precursors in earlier diagnosis and monitoring of myeloma bone disease.Clinical utility of C-terminal telopeptide of type 1 collagen in multiple myeloma.
P2860
Q26783464-F37CBEE1-1DFE-4B56-99F1-032AC894AF40Q28082335-56E7932F-4F71-4148-8F4F-05517F66EA0FQ34038854-C500CC22-F45F-4063-BB5C-3C8D6FEFCFF3Q34423112-06BDCB31-4E52-421E-A1C2-5BCBEB166B6CQ34718186-7EE423F9-4DD2-4E82-9E54-6B826461509DQ35035011-EA2DBAE7-D745-4A3D-A22E-56E430C6EFC2Q35422468-72FB8408-8035-4E8B-853B-040C82CCD1EAQ35623636-1C548D5C-1826-4006-8414-C2DA60E82A10Q36288753-3556B4CB-B9BB-4C4D-92C8-84D1C9878E4AQ36929923-6145927A-2EB1-477A-B97E-7783FF509B1CQ37166798-38B570F4-225A-40F9-8ED9-01A888E73EDBQ38002942-D0E4E51A-8BCF-4580-948A-3E0D0E2DF7B8Q38039879-0F147AD4-0F15-4407-9AD2-EC4E95A81EADQ38179039-CF977177-FFC0-4680-B5AA-E65E150A2228Q38748577-7E47DE56-9F00-4479-9003-4571EFC65F59Q38932298-23BF2081-74C2-4D94-8E89-EA013314F207Q38979865-28D90BE4-64A5-423B-9F73-91BC45A51BEEQ39153978-20C4B1AE-EDEA-45F3-8934-C817E84AF254Q39212192-7E777272-3F53-41C7-BD44-C1863A075AB8Q40108030-3517C236-7183-4AA0-830A-1B95D7FF1C94Q40485837-5C92D7F4-3D25-4073-B35A-1AECEAA618C8Q41586677-DF3A63DD-66CE-4596-AF18-078ADF4C1C19Q42355444-5CAEB177-E868-4030-A9BB-F3D481A9E62EQ43965394-5C8BA78B-BA89-43DC-A30F-B76E49B7498DQ45235765-E0BEF6BE-9177-46B6-B383-63B222953C81Q46057559-065B7119-75F8-4A06-B4EC-4DA748636C37Q48049809-F4C71417-1362-417B-BDDE-957BF8BD3190Q48283228-73D64C39-23E3-43F0-9D64-F4D6576DD13BQ48910291-DFE04DBD-7B7A-4071-AEA0-9C187B53224FQ51564235-7A23733C-71AD-4168-B598-144B2A62C8B2Q52872947-395408E8-F522-4DFE-A544-F723C6E13879Q53206311-8BA63F84-F0D2-45B6-95F1-8A1A9285189B
P2860
The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The use of biochemical markers ...... ational Myeloma Working Group.
@en
The use of biochemical markers ...... ational Myeloma Working Group.
@nl
type
label
The use of biochemical markers ...... ational Myeloma Working Group.
@en
The use of biochemical markers ...... ational Myeloma Working Group.
@nl
prefLabel
The use of biochemical markers ...... ational Myeloma Working Group.
@en
The use of biochemical markers ...... ational Myeloma Working Group.
@nl
P2093
P50
P356
P1433
P1476
The use of biochemical markers ...... ational Myeloma Working Group.
@en
P2093
A Chanan-Khan
B G M Durie
J-L Harousseau
K C Anderson
N Abildgaard
P2888
P304
P356
10.1038/LEU.2010.173
P577
2010-09-02T00:00:00Z
P5875
P6179
1048496341